Eye Health News and Research

Latest Eye Health News and Research

Schepens Eye Research Institute scientist selected for Otto Schade Prize

Dr. Eli Peli, a senior scientist at Schepens Eye Research Institute, has been selected by the Society for Information Display for the Otto Schade Prize. Peli will receive the award at a special presentation at the Society's Awards Banquet on May 24, 2010 in Seattle.

4 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

With summer right around the corner, more people will be spending time outdoors and UV protection will be top of mind. Unfortunately, most people think about the protection of their skin, when they should also be considering the safety of their eyes. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, only one-third of Americans said UV protection is the most important factor they consider when purchasing sunglasses.

3 May 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International today announced first quarter financial results for 2010.

3 May 2010

Progress in development of gene therapies for inherited blindness caused by rod degeneration

Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.

3 May 2010

Report shows increasing rates of AMD among Asians

The May issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes a surprising, first report on increasing rates of age-related macular degeneration among Asians, and describes an innovative "bypass" laser surgery that may help many people with central retinal vein occlusion avoid serious vision loss.

3 May 2010

Measuring children's blood pressure is complicated: Researchers

A Johns Hopkins Children's Center study of 2,500 patient records suggests that medical staff fails to check a child's blood pressure a fifth of the time, and is not recognizing what constitutes an abnormal reading in those whose blood pressure they do check.

3 May 2010

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos, the largest and fastest growing minority population in the United States.

3 May 2010

Officials face challenges in writing new health law regulations

Obama administration officials face a "monumental task" in writing new regulations to the health care law while keeping one eye on public perception ahead of November's midterm elections.

30 Apr 2010

Kidney transplant recipients have higher risk of cancer: Researchers

Kidney transplant recipients are known to have a higher risk of cancer, compared to the general population, due to the need to take immunosuppressive drugs to prevent organ rejection. Results published today from a significant, long-term study suggest that no single medication appears to increase this cancer risk.

30 Apr 2010

NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay Pharmaceuticals, Inc. announced today that the latest public data on its Aganocide® compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology annual meeting in Fort Lauderdale, Florida.

30 Apr 2010

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

While most headaches in children can be treated with over-the-counter pain medications or lifestyle changes, it is important to pay attention to their symptoms in case they herald something more serious.

30 Apr 2010

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that no single medication is to blame for the higher incidence of cancer seen among patients who have undergone transplantation.

30 Apr 2010

Eye Health News and Research

Latest Eye Health News and Research

Schepens Eye Research Institute scientist selected for Otto Schade Prize

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Progress in development of gene therapies for inherited blindness caused by rod degeneration

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Report shows increasing rates of AMD among Asians

Measuring children's blood pressure is complicated: Researchers

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Officials face challenges in writing new health law regulations

Kidney transplant recipients have higher risk of cancer: Researchers

NovaBay to present data on Aganocide compounds at ARVO annual meeting

IRIDEX commences commercial shipment of IQ 532 laser systems

ISTA Pharmaceuticals first-quarter net revenues up 39%

pSivida announces presentations on bioerodible technologies for degenerative eye disease

REGN reports net loss of $30.5M for first-quarter 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

Genetics & Genomics - Second Edition eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in